ZM 447439

製品コードS1103

ZM 447439化学構造

分子量(MW):513.59

ZM 447439は一種の選択性的で、ATP競争性的なオーロラAとオーロラ Bの阻害剤で、IC50値が110 nMと130 nMです。ZM 447439は、オーロラA/オーロラ Bに作用する選択性はMEK1、 SrcとLckに作用する選択性より8倍がそれぞれ高くなりますが、CDK1/2/4、Plk1とChk1等に作用する効果が殆どありません。

サイズ 価格 在庫  
USD 123 あり
USD 88 あり
USD 138 あり
USD 340 あり
USD 592 あり

カスタマーフィードバック(3)

  • p31comet depletion delays MCC disassembly even with the proteasome inhibited. (A) FACS analysis of HeLa Tet-on cells transfected with control or p31comet siRNA and then treated with Taxol followed by Aurora B inhibition with ZM447439. The percentage of mitotic cells (cells that have 4N DNA content and are MPM2 positive) is shown for each sample.

    Mol Biol Cell 2011 22, 4227-35. ZM 447439 purchased from Selleck.

    HeLa cells were treated with Nocodazole (100ng/ml) (Lanes 2-4) or Taxol (1µM) (Lanes 6-8) or DMSO (lanes 1, 5) for 16h. The indicated inhibitors were added for 2h (1 µM) before harvesting the cells. The p-Aurora-A (T288), B (T232), C (T198) antibody was from Cell Signaling (#2914). MK5108 is an Aurora-A inhibitor. VX680 inhibits all three Aurora kinases. ZM447439 inhibits both Aurora-B and -C kinases, but not Aurora-A kinase.

    Dr. Yuanhong Chen of University of Nebraska. ZM 447439 purchased from Selleck.

  • Western blot analysis of Histone and Aurora kinase. 0-10μM ZM447439 was added.

    Dr. Zhang of Tianjin Medical University. ZM 447439 purchased from Selleck.

製品安全説明書

Aurora Kinase阻害剤の選択性比較

生物活性

製品説明 ZM 447439は一種の選択性的で、ATP競争性的なオーロラAとオーロラ Bの阻害剤で、IC50値が110 nMと130 nMです。ZM 447439は、オーロラA/オーロラ Bに作用する選択性はMEK1、 SrcとLckに作用する選択性より8倍がそれぞれ高くなりますが、CDK1/2/4、Plk1とChk1等に作用する効果が殆どありません。
特性 An Aurora selective ATP-competitive inhibitor.
ターゲット
Aurora A [1] Aurora B [1] LCK [1] Src [1] MEK1 [1]
110 nM 130 nM 880 nM 1.03 μM 1.79 μM
体外試験

In vitro, ZM-447439 selectively inhibits recombinant human Aurora A and B with IC50 values of 110 and 130 nM, respectively, while other protein kinases of diverse structural types including the mitotic kinases CDK1 and PLK1 are inhibited with IC50 values >10 μM. [1] Aurora kinase inhibitor, ZM-447439 time- and dose-dependently inhibits the growth of all three cell lines with IC50 values of 3 μM (BON), 0.9 μM (QGP-1) and 3 μM (MIP-101) after 72 hours of continuous exposure. In addition, ZM-447439 potently induces cell apoptosis by promoting DNA fragmentation and caspase 3 and 7 activation, and arrests GEP-NET cells in the G0 /G1and G2/M phase of the cell cycle. [2] In mouse embryo, inhibition of Aurora kinase activity by ZM-447439 results in abnormalities during mitosis by regulating the phosphorylation of histone H3 serine 10 (H3S10Ph) from G2 to metaphase with different perturbations in each embryonic cycle. [3] A recent study shows that ZM-447439 exhibits growth inhibitory and proapoptotic effect on cervical cancer SiHa cells, and enhances the chemosensitivity to cisplatin. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{n3VWlvcGmkaYTpc44hd2ZiaIXtZY4hTW:OLUGtZ4VtdCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUi2O|gh|ryP NXPiS4piW0GQR1XS
MCF7 cell MUfQdo9tcW[ncnH0bY9vKGG|c3H5 M1T5ZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgUWNHPyClZXzsJIxqdmVuIFnDOVA:OC5zOUig{txO Mk\jNVY{OzdzMkK=
human P12-ICHIKAWA cell NXW2b4dnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFj5UpRKdmirYnn0bY9vKG:oIHj1cYFvKFBzMj3JR2hKU0GZQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlI1PDFizszN M1zTNnNCVkeHUh?=
human KARPAS-45 cell M2\4eGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mk\wTY5pcWKrdHnvckBw\iCqdX3hckBMSVKSQWOtOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN6MUK4JO69VQ>? NV\1PWx{W0GQR1XS
human ES3 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYS4ZWhGUW6qaXLpeIlwdiCxZjDoeY1idiCHU{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ4OzJizszN MYTTRW5ITVJ?
human ES8 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGVUQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNEm4NFYh|ryP MoLMV2FPT0WU
human TE-11 cell M{TTbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn;oTY5pcWKrdHnvckBw\iCqdX3hckBVTS1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVM4ODNizszN MoXGV2FPT0WU
human RS4-11 cell MnPaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1z0RWlvcGmkaYTpc44hd2ZiaIXtZY4hWlN2LUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42PTR2IN88US=> MYHTRW5ITVJ?
human MOLT-16 cell NXrtT29nT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV3Jcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlYxQTZzIN88US=> Mk\IV2FPT0WU
human RKO cell M4ezW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NULI[nZNUW6qaXLpeIlwdiCxZjDoeY1idiCUS1:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlcxPjV4IN88US=> NGTlUllUSU6JRWK=
human MV-4-11 cell NVKzdm1PT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYradpV5UW6qaXLpeIlwdiCxZjDoeY1idiCPVj20MVEyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC55OU[zJO69VQ>? NH;Qe3dUSU6JRWK=
human SW954 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnvvTY5pcWKrdHnvckBw\iCqdX3hckBUXzl3NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPFM3OzVizszN Mk\5V2FPT0WU
human BE-13 cell MlrES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4T0OGlvcGmkaYTpc44hd2ZiaIXtZY4hSkVvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg1PDF6IN88US=> M2Lp[HNCVkeHUh?=
human MOLT-4 cell NF3QOGhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWLJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPFk6PzhizszN NFzYTplUSU6JRWK=
human NBsusSR cell NEfTeZlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoLFTY5pcWKrdHnvckBw\iCqdX3hckBPSnO3c2PSJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46OTN6NzFOwG0> MlrzV2FPT0WU
human H9 cell NInRW5NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnL1TY5pcWKrdHnvckBw\iCqdX3hckBJQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOUK5O|kh|ryP NGXDSXJUSU6JRWK=
human A172 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIW3U|VKdmirYnn0bY9vKG:oIHj1cYFvKEFzN{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk5PDFzIN88US=> MnTGV2FPT0WU
human ES5 cell M2TPc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4HpXmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6wNFI1QCEQvF2= MXjTRW5ITVJ?
human SBC-1 cell NIqzT3FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXnJcohq[mm2aX;uJI9nKGi3bXHuJHNDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6wN|kzQCEQvF2= M2ftUXNCVkeHUh?=
human NCI-H209 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVLJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkC5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yPjZyMjFOwG0> NVPw[JlHW0GQR1XS
human NKM-1 cell NHrhNJlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3jKfmlvcGmkaYTpc44hd2ZiaIXtZY4hVkuPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlE3Pzl6IN88US=> M{LqUnNCVkeHUh?=
human NCI-H720 cell NIDnPFdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYPJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{KwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zODZ{NzFOwG0> NWDTeWgzW0GQR1XS
human KE-37 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mmn5TY5pcWKrdHnvckBw\iCqdX3hckBMTS1|NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNlE{QDhizszN MVPTRW5ITVJ?
human SW48 cell NV7LZoVpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3HJS2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d2ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNlMyPTVizszN NVS3O4FGW0GQR1XS
human IST-SL1 cell NWDnSY06T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIGwbWFKdmirYnn0bY9vKG:oIHj1cYFvKEmVVD3TUFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjNzN{K3JO69VQ>? NWf1dIdwW0GQR1XS
human SK-NEP-1 cell NI\hU2dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUPJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU6HUD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{PjR7ODFOwG0> M33jOHNCVkeHUh?=
human NOMO-1 cell NYXCe5pJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX\pRo14UW6qaXLpeIlwdiCxZjDoeY1idiCQT13PMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjN4N{K1JO69VQ>? MWnTRW5ITVJ?
human DOHH-2 cell MkfWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEPxbVVKdmirYnn0bY9vKG:oIHj1cYFvKESRSFitNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPDB{N{[g{txO M1vvVXNCVkeHUh?=
human ABC-1 cell NVHucVZwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1r5WWlvcGmkaYTpc44hd2ZiaIXtZY4hSUKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQxOzV{IN88US=> M{iyRnNCVkeHUh?=
human Ramos-2G6-4C10 cell NE\z[WJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3KzNWlvcGmkaYTpc44hd2ZiaIXtZY4hWmGvb4OtNmc3NTSFMUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQxPjB3IN88US=> NIP5fpZUSU6JRWK=
human EM-2 cell M2fQe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXnJcohq[mm2aX;uJI9nKGi3bXHuJGVONTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkSxO|IyKM7:TR?= MX3TRW5ITVJ?
human NB14 cell M1rxemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV3Jcohq[mm2aX;uJI9nKGi3bXHuJG5DOTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkW1OlIyKM7:TR?= NGrlfFBUSU6JRWK=
human MOLT-13 cell M4LhfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1q0SGlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTZ5ME[g{txO NF7acXRUSU6JRWK=
human ECC10 cell NW\wVJUzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYfVdY1oUW6qaXLpeIlwdiCxZjDoeY1idiCHQ1OxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjN|NUOg{txO MYjTRW5ITVJ?
human LK-2 cell NF3hU4tIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVraPWRrUW6qaXLpeIlwdiCxZjDoeY1idiCOSz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43PDV7NDFOwG0> M4nDO3NCVkeHUh?=
human CTB-1 cell NEK3OXhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NU\MV4pkUW6qaXLpeIlwdiCxZjDoeY1idiCFVFKtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjdyOEKg{txO Ml;aV2FPT0WU
human NCI-H1581 cell M1zod2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2LybWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVgyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS54N{W1JO69VQ>? Mn;lV2FPT0WU
human COLO-800 cell MkTlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4XWOWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz24NFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjdyM{iyJO69VQ>? MYDTRW5ITVJ?
human NB7 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYfUem86UW6qaXLpeIlwdiCxZjDoeY1idiCQQkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlc2Ojl5IN88US=> NInnN|dUSU6JRWK=
human LAMA-84 cell M17xdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGHqeIhKdmirYnn0bY9vKG:oIHj1cYFvKEyDTVGtPFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjd3NUKg{txO NHPS[FJUSU6JRWK=
human HCT-116 cells NXnGRo01T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVnJcohq[mm2aX;uJI9nKGi3bXHuJGhEXC1zMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlgxQTB6IN88US=> MW\TRW5ITVJ?
SK-UT-1 cell NU\1eJJ4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFP1d4NKdmirYnn0bY9vKG:oIHj1cYFvKFONLWXUMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjhzNUOg{txO MXHTRW5ITVJ?
human H4 cell M4S1RWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkHFTY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwOEG1O|gh|ryP MlLpV2FPT0WU
human CAL-51 cell NXjndWZOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4TVUWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45Ozh2NTFOwG0> NWHVWIY4W0GQR1XS
human LoVo cells MVvQdo9tcW[ncnH0bY9vKGG|c3H5 MXS3NkBp MnfDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCOb2\vJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGStZoF{\WRiV2PUPEBz\WGpZX70JIF{e2G7LDDJR|UxRTFwOTFOwG0> MYOyOVI4ODRyMx?=
human HN cell M{jHbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGhPKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS57MkWxJO69VQ>? NVv0Vlg3W0GQR1XS
human L-363 cell NYq5W5NPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUjJcohq[mm2aX;uJI9nKGi3bXHuJGwuOzZ|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT65OVEzKM7:TR?= MVfTRW5ITVJ?
human NCI-H747 cell NVjwNYF5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlPzTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEe0O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvODN|NUOg{txO MoXEV2FPT0WU
human A498 cell NILFV5NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3PEc2lvcGmkaYTpc44hd2ZiaIXtZY4hSTR7ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuN|Y3QSEQvF2= NGPQWpdUSU6JRWK=

多くの細胞株試験データを見る場合、クリックしてください

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

In vitro kinase assays :

Recombinant Aurora A and B are expressed as NH2-terminal His6-tagged fusion proteins using a baculovirus expression system. Aurora A is purified by affinity chromatography using Ni-NTA agarose, and Aurora B is purified by ion exchange chromatography using CM Sepharose Fast Flow. 1 ng purified recombinant enzyme is added to a reaction cocktail containing 25 mM Tris-HCl, pH 7.5, 12.5 mM KCl, 2.5 mM NaF, 0.6 mM DTT, 6.25 mM MnCl2, 10 μM peptide substrate, 10 μM for Aurora A or 5 μM ATP for Aurora B, and 0.2 μCi γ-[33P]ATP (specific activity ≥2,500 Ci/mmol), and is then incubated at RT for 60 minutes. Reactions are stopped by addition of 20% phosphoric acid, and the products are captured on P30 nitrocellulose filters and assayed for incorporation of 33P with a BetaplateTM counter. No enzyme and no compound control values are used to determine the concentration of ZM447439, which gave 50% inhibition of enzyme activity. Further details are available on request from Nicholas Keen.
細胞試験: [2]
+ 展開
  • 細胞株: BON, QGP-1 and MIP-101 cells
  • 濃度: 0-5 μM
  • 反応時間: 72 hours
  • 実験の流れ: Cell number is evaluated by crystal violet staining. In brief, cells in 96-well plates are fixed with 1% glutaraldehyde. Then cells are stained with 0.1% crystal violet. The unbound dye is removed by washing with water. Bound crystal violet is solubilized with 0.2% Triton X-100. Light extinction which increases linearly with the cell number is analyzed at 570 nm using an ELISA reader.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 103 mg/mL (200.54 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
体内 順序で溶剤を入れること:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 513.59
化学式

C29H31N5O4

CAS No. 331771-20-1
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

Aurora Kinase信号経路図

Aurora Kinase Inhibitors with Unique Features

相関Aurora Kinase製品

Tags: ZM 447439を買う | ZM 447439 ic50 | ZM 447439供給者 | ZM 447439を購入する | ZM 447439費用 | ZM 447439生産者 | オーダーZM 447439 | ZM 447439化学構造 | ZM 447439分子量 | ZM 447439代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID